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Abstract
Background: Chronic lymphocytic leukemia (CLL) is characterized by accumulation of mature
appearing lymphocytes and is rarely complicated by thrombosis. One possible explanation for the
paucity of thrombotic events in these patients may be the presence of the ecto-nucleotidase CD39/
NTDPase-1 on the surface of the malignant cells in CLL. CD39 is the major promoter of platelet
inhibition in vivo via its metabolism of ADP to AMP. We hypothesize that if CD39 is observed on
CLL cells, then patients with CLL may be relatively protected against platelet aggregation and
recruitment and that CD39 may have other effects on CLL, including modulation of the disease, via
its metabolism of ATP.
Methods: Normal and malignant lymphocytes were isolated from whole blood from patients with
CLL and healthy volunteers. Enzyme activity was measured via radio-TLC assay and expression via
FACS. Semi-quantititative RT-PCR for CD39 splice variants and platelet function tests were
performed on several samples.
Results: Functional assays demonstrated that ADPase and ATPase activities were much higher in
CLL cells than in total lymphocytes from the normal population on a per cell basis (p-value <
0.00001). CD39 activity was elevated in stage 0–2 CLL compared to stage 3–4 (p < 0.01). FACS of
lymphocytes demonstrated CD39 expression on > 90% of normal and malignant B-lymphocytes
and ~8% of normal T-lymphocytes. RT-PCR showed increased full length CD39 and splice variant
1.5, but decreased variant 1.3 in CLL cells. Platelet function tests showed inhibition of platelet
activation and recruitment to ADP by CLL cells.
Conclusion: CD39 is expressed and active on CLL cells. Enzyme activity is higher in earlier stages
of CLL and decreased enzyme activity may be associated with worsening disease. These results
suggest that CD39 may play a role in the pathogenesis of malignancy and protect CLL patients from
thrombotic events.
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Background
Chronic lymphocytic leukemia (CLL) is one of the most
common leukemias in North America, representing 25–
30% of all leukemias, with 10,020 new cases and 4660
deaths estimated for 2006 [1,2]. The leukemia is charac-
terized by a clonal expansion of long-lived, mature
appearing B-lymphocytes that co-express the CD5, CD19,
and CD23 surface antigens [3]. In contrast to many other
malignancies, CLL is not known to be associated with an
increased risk of thrombosis [4]. Patients with thrombosis
in CLL have been reported, but most occur in association
with acquired inhibitors of anti-thrombotic moieties [4-
6]. Conversely, there are only a few case reports in the lit-
erature of abnormal hemorrhage in CLL patients [7-9]. In
addition, successful completion of pregnancies uncompli-
cated by thrombotic events have been reported in patients
with CLL [10,11], suggesting that these patients can with-
stand pro-thrombotic states. Two recent studies of cell sur-
face molecules in CLL show that they express many of the
same markers as activated normal B-cells including CD39
[12,13]. Although CLL cells resemble activated B-cells,
they function more like anergized B-lymphocytes. There-
fore, some of the cell surface markers observed usually
associated with activated B-cells may be inactive in CLL.
No studies of the activity of CD39 in CLL have been per-
formed to date.
CD39 (ecto-nucleotidase, NTDPase1), is an ADPase and
ATPase found on the surface of endothelial cells, normal
lymphocytes, and other leukocytes [14,15]. It is strongly
expressed on peripheral B-lymphocytes, weakly expressed
on marginal zone B-lymphocytes, but not on B-lym-
phocytes in germinal centers [16,17]. Its principal func-
tion on the endothelial cell surface is to decrease platelet
activation and recruitment by metabolizing platelet-
released ADP. In leukocytes, the enzyme has a variety of
other effects as well, including modulation of cytokine
expression and the inflammatory response [18,19], as
well as cell-cell adhesion [14]. CD39 will quickly metabo-
lize the ADP produced by its metabolism of ATP to AMP.
The enzyme is usually more efficient in metabolizing ADP
than ATP [20]. Five apyrase conserved regions on the mol-
ecule are essential for preservation of CD39 enzyme activ-
ity [21].
A decreased ratio of ADPase: ATPase activity in lym-
phocyte CD39 has been reported in patients with coro-
nary artery disease [22], suggesting that inefficient or
aberrant CD39 activity may be involved in the pathogen-
esis of arterial vascular disease. Variation of the
ADPase:ATPase ratio has been observed between individ-
uals, although intra-personal variation has not yet been
observed. Although very low levels of CD39 expression on
platelets has been reported [23,24], our laboratory found
no difference between ATPase and ADPase activity in
platelet-rich and platelet-poor plasma. This suggests that
the contribution of platelet CD39 is minimal to non-exist-
ent and that leukocyte and endothelial cell CD39 exert
primary control of ATP and ADP conversion to ADP and
AMP (unpublished data). Pharmacological data in ani-
mals suggests that supra-physiologic levels of CD39 are
not associated with clinical hemorrhagic episodes [25]
Transgenic mice which over-expressed CD39 showed a
prolonged bleeding time but did not show overt bleeding
tendencies and had no increase in bleeding associated
with parturition or routine experimental procedures.
Additionally, these mice were protected against thrombo-
sis induced by injection of ADP or collagen [23]. CD39
has also been shown in a murine model of xengraft rejec-
tion to be protective against early rejection by reducing
platelet reactivity [23].
Aberrations in CD39 expression have been observed in
other neoplastic disorders. One publication noted
increased expression of CD39 in vitro in a differentiated
human melanoma cell line as compared with normal
melanocytes. Decreased CD39 expression was seen in less
differentiated sub-clones, with the least differentiated cell
lines expressing far less activity than normal melanocytes
[26]. A study of CD39 activity in pancreatic cancer
reported decreased activity in smooth muscle cells sur-
rounding the ducts in the malignant tissue as compared
with normal pancreatic tissue [27]. An in vitro study of
myeloid cancer lines found that CD39 was not expressed
on myeloblasts, but was expressed on later myeloid cell
lines [28]. This finding is particularly interesting as acute
myeloid leukemia is associated with increased thrombo-
sis, whereas chronic myeloid leukemia is less so[29,30]. In
this report, we studied the role of CD39 in CLL and con-
sidered the implications of this role in both CLL and vas-
cular biology in general.
Methods
Patient population
Patients were recruited from the hematology clinic and
inpatient hematology/oncology service at the VA Harbor
Healthcare System and Weill Medical College of Cornell
University. The protocol was approved by the Institu-
tional Review Boards at both institutions. The diagnosis of
CLL was made by the presence of the characteristic immu-
nophenotype (CD5+, CD19+, CD23+, sIg dim). Patients
with CLL were asked to participate in the study if they
were able to give informed consent, had a hemoglobin of
> 8 and had no contraindications to a blood donation.
After informed consent was obtained, 10–50 ml of whole
blood was withdrawn via free flow from each donor.
Blood was drawn from healthy volunteers to be used as a
control population.Journal of Translational Medicine 2007, 5:23 http://www.translational-medicine.com/content/5/1/23
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Lymphocyte isolation
Lymphocytes were isolated according to a modified histo-
paque isolation protocol. Whole blood was centrifuged
and platelet-rich plasma removed. Phosphate buffered
saline (PBS) was added to the remaining blood to restore
the original plasma volume. Blood was then diluted 1:1
with PBS and carefully layered on a histopaque gradient.
Samples were centrifuged for 30 minutes at 820 g, the
buffy coat isolated and washed with PBS × 3. The cells
were then counted. In cases in which > 90% lymphocytes
were present, no further isolation was needed. In cases in
which < 90% lymphocytes were present, cells were incu-
bated in RPMI with 10% fetal calf serum (FCS) for 30
minutes × 2 to deplete monocytes, which adhered to the
bottom of the flask. Lymphocytes remaining in fluid
phase were washed with PBS, and re-counted. Short term
FCS exposure (< 24 hours) did not affect CD39 expression
or activity. Cell purity as assessed by FACS was > 80% CLL
lymphocytes. In cases where the purity of CLL cells was
less than 80%, an alternate isolation technique, described
below was used.
B-lymphocytes were isolated using the RosetteSep (Stem-
Cell, Vancouver) B-lymphocyte isolation kit per the man-
ufacturer's protocol. The RosetteSep B-lymphocyte
isolation kit uses bispecific antibodies against CD2, CD3,
CD16, CD36, CD56, CD66b, and glycophorin A to
deplete non-B-lymphocytes from the histopaque layer.
Since the antibody cocktail does not include CD5, it
should not deplete CLL lymphocytes. B-lymphocytes were
isolated from controls and from two patients who had
small CLL clones. In all other cases, > 80% of total lym-
phocytes were malignant and therefore CD39 activity in
total lymphocytes was considered to be the equivalent of
activity in malignant lymphocytes.
Assay for ADPase and ATPase activity/TLC
To assay CD39 activity, cell suspensions were incubated
with 50 μmolar 14C-labeled ADP or ATP in 50 μliter assay
buffer for five minutes and the reaction terminated by
addition of a "stop solution". The stop solution consisted
of 160 mM EDTA at a pH of 7 and 17 mM ADP in 0.9%
saline[31]. Suspended cells were then removed by centrif-
ugation and the supernatant decanted for analysis of the
reaction. Thin-layer chromatography (TLC) was used to
separate labeled nucleotides, nucleosides, and bases.
Their radioactivity was then analyzed to assess metabo-
lism of 14C-labeled ADP or ATP by CD39. Data are
expressed as a percentage of ADP or ATP metabolized or
as picomoles nucleotide metabolized per minute per
50,000 or 100,000 cells. This TLC system was developed
in our laboratory [22,31,32].
FACS analysis
Cells were single stained with CD3-APC, CD19-FITC,
CD39-PE, CD4-PERCP, and CD8-FITC (CD19-FITC and
CD39-PE Ancell, all others BD Biosciences). The CD39
antibody used was BU-61, an antibody that identifies full-
length CD39 and some, but not all of the splice variants
identified (see below). The splice variants we identified do
not occur in isolation, but are always associated with full-
length CD39. Therefore, it is unlikely that the percentage
positive cells would change if another antibody were
used, although there could be some change in the per cell
density identified by FACS. Cells were also double stained
for CD3/CD39, CD4/CD39, CD8/CD39, and CD19/
CD39. Cells plus antibody were incubated for 45–90 min-
utes at room temperature with shaking. Acquisition and
analysis of FACS data was performed on FACSCanto (BD
Biosciences) using FACSDiva software (BD Biosciences).
Percentage positivity and geometric mean fluorescence for
normal and malignant lymphocytes were examined.
Isolation of RNA and conversion to cDNA
Cells remaining after activity assay were pelleted and fro-
zen at -70°C. RNA was isolated via Trizol (Invitrogen) per
manufacturer's protocol and cDNA produced by incuba-
tion with reverse transcriptase.
Semiquantitative RT-PCR
cDNA from patients and normal controls was produced as
above and evaluated for CD39 by semi-quantitative PCR.
We used primers that identify splice variants as well as full
length CD39 to determine whether any differences in
expression of splice variants were present between normal
lymphocytes and CLL cells.
Platelet reactivity studies
Platelet-rich plasma (PRP) and lymphocytes were pre-
pared from patients with CLL. PRP was prepared by cen-
trifuging whole blood from patients at 200 g for 15
minutes, removing the plasma layer, and re-centrifuging
this at 90 g for 10 minutes to remove any residual eryth-
rocytes. Platelet-poor plasma was prepared by centrifug-
ing an aliquot of PRP at 3000 g for 3 minutes in an
Eppendorf centrifuge and removing the supernatant.
Lymphocytes were prepared as above. Platelet aggregation
curves were developed with PRP, using ADP at 1, 2, 5, and
10 μM. 0.5–1 × 106 CLL lymphocytes were then added to
PRP and platelet-poor plasma (PPP) controls. The aggre-
gation response to ADP was measured and recorded
[21,33].
Statistics
Student's two sided T-test with unequal variance was used
to generate p-values when comparing groups.Journal of Translational Medicine 2007, 5:23 http://www.translational-medicine.com/content/5/1/23
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Results
Patient clinical data
Blood samples from 21 patients (3 women, 18 men) from
the two institutions were drawn for this study. Three
patients underwent more than one blood donation.
Few of the patients had a history of thrombotic events or
hemorrhage before or after the diagnosis of CLL was
made. One patient had a history of stroke diagnosed prior
to the onset of CLL and one had a history of heart disease
and deep venous thrombosis prior to his diagnosis. Nei-
ther patient had any further events after diagnosis. Patient
characteristics are summarized in Table 1.
Total lymphocytes were isolated from 22 healthy volun-
teers (9 women, 13 men) for use as a control population.
In preliminary studies, it became clear that CD39 expres-
sion varied between B-lymphocytes and T-lymphocytes.
Therefore, B-lymphocytes were isolated from an addi-
tional 8 volunteers. None of the normal donors had a his-
tory of thrombotic events or hemorrhage.
Radio-TLC data
ADPase and ATPase activities were observed in malignant
lymphocytes from all patients. However, the level of activ-
ity varied greatly. ADPase ranged from 4.3 to 1263 pmol/
min/50 K cells and ATPase ranged from 7.2 to 70 pmol/
min/50 K cells. Greater ADPase activity was seen in
patients with stage 0–2 disease (p = 0.002), hemoglobin
greater than 13 (p = 0.03), and patients who were over 70
years of age (p = 0.002). A trend toward lower activity was
seen in patients who had undergone chemotherapy and
those with leukocyte counts of greater than 20 × 103 per
μl, but the p-values were non-significant (p = 0.08 and
0.15 respectively), possibly due to the small sample size
(Table 2). Because of the relatively small numbers of
patients studied thus far, we were unable to perform mul-
tivariate analysis and so cannot make definitive state-
ments as to whether all the variables identified are
independent. No correlation between gender, ethnic ori-
gin, platelet count, or duration of disease and CD39 activ-
ity was observed. In controls, CD39 activity did not vary
with age, gender, ethnic origin, or any hematologic
parameter. In a previous study, decreased CD39 activity
was observed in patients with heart disease and hyperten-
sion but no correlation with age was observed (18).
Repeat sampling was performed when clinical indications
of worsening disease were observed. Samples were col-
lected prior to institution of therapy. Among the patients
who had repeat sampling after worsening of disease, two
of three had decreased CD39 activity. The other patient
had decreased ATPase activity, but slightly increased
ADPase activity. Interestingly, this patient had an increase
in the density of CD39 expression per cell as observed by
FACS of about double (see below), suggesting that activity
per molecule decreased in this patient as well.
CD39 activity was much greater in CLL cells than in nor-
mal lymphocytes. However, CLL is a disease of B-lym-
phocytes and we have found that normal B-lymphocytes
express CD39 at higher levels and on a larger percentage
of cells than T-lymphocytes. Therefore, B-lymphocytes
were isolated from 8 normal controls and compared to
the malignant lymphocytes from CLL patients. No signif-
icant difference was found between CD39 activity in nor-
mal B-lymphocytes and malignant lymphocytes in CLL
patients. However, normal B-lymphocytes showed mildly
decreased activity compared to stage 0–2 CLL and
increased activity compared to stage 3–4 CLL (Figure 1).
Lack of the IgVH gene mutation is a known poor prognos-
tic factor in CLL. It is possible that both lack of the IgVH
mutation and low CD39 activity result from malignant
transformation of less mature cells. However, this does
not explain all of the differences in CD39 activity between
early and later stage CLL since IgVH mutational status
does not change throughout the course of the disease.
Table 1: Clinical characteristics of patients studied
Age 71.5 y/o (35–95 y/o)
Gender Male 18
Female 3
Date of diagnosis 1990–2005
Stage 0 9
12
22
3–4 8
History of chemotherapy Yes 10
No 11
Clinical characteristics of patients in this study. A gender imbalance is seen because the majority of patients were recruited from the VA hospital 
system.Journal of Translational Medicine 2007, 5:23 http://www.translational-medicine.com/content/5/1/23
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FACS data
FACS for CD39 was obtained on 14 patients and 8 con-
trols. As expected, patients showed a much higher per-
centage of CD39 expression on total lymphocytes (71
versus 21%, p < 10-7). Expression on normal B-lym-
phocytes versus all CLL cells did not differ significantly
(93% versus 95%, p = 0.5). CD39 expression was greater
in CLL patients who had not received chemotherapy than
in those who had (99% versus 89%), but the difference
was not statistically significant (p = 0.1), perhaps because
of a wider variation in CD39 expression in CLL cells as
opposed to normal B-lymphocytes.
Mean per cell expression of CD39 was similar on CLL cells
as compared to normal B-lymphocytes (Table 3). How-
ever, the range of expression on CLL cells was extremely
large, with a geometric mean ranging from 600 to 10,750
in CLL, versus 2100–4600 in normal B-lymphocytes, pos-
sibly indicating the presence of multiple sub-groups,
some of which had higher levels of expression, others
lower. Interestingly, expression of CD39 by FACS was not
always well correlated with CD39 function as measured
by radio-TLC. Two patients who progressed during the
study had FACS measurement of CD39 levels both before
and after progression of the disease. In both cases, the per-
centage cells positive for CD39 was essentially
unchanged. However, in the first instance, the geometric
mean decreased by approximately a factor of four,
whereas in the second, the geometric mean actually
increased by 2–3 times. ADPase and ATPase function
decreased by about 50% in the first case, but ADPase was
slightly increased in the second although ATPase
decreased slightly in the setting of increased CD39 expres-
sion. The reason for this difference is not clear from cur-
rent information, although the observation suggests that
CD39 may become less functional as CLL evolves, even in
cases where its expression is unaltered or even increased.
Characterization of CD39 expression on normal lym-
phocytes showed a variation between expression on T-
lymphocytes and B-lymphocytes. Whereas over 90% of B-
lymphocytes express CD39, only a minority (~8% of
CD3+ cells) of T-lymphocytes expressed the enzyme.
Expression in CD4+ cells and CD8+ cells was similar
(Table 3). Geometric mean expression in normal T-lym-
phocytes tended to be lower than expression in normal B-
lymphocytes and in CD8+ cells compared to CD4+ cells
CD39 activity as measured in normal and malignant lym- phocytes Figure 1
CD39 activity as measured in normal and malignant lym-
phocytes. The enzyme was measured by radio-TLC as 
described in methods. ADPase and ATPase activity was ele-
vated in cells of all CLL patients, early (stage 0–2) CLL, and 
late (stage 3–4) CLL as compared to normal lymphocytes (p 
< 0.00001 for all and early CLL versus normal lymphocytes; p 
< 0.05 for late CLL). ADPase activity was elevated in early 
CLL versus normal B-lymphocytes (p = 0.05) but decreased 
in late CLL (p < 0.01).
Activity of CD39 in Normal and Malignant Cells
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Table 2: Characteristics associated with changes in CD39 function
Characteristics Activity (pmol/min/50 K cells)
Stage 0–2 88.2*
3–4 44.7
History of chemotherapy? Yes 55.8
No 83**
Age < = 70 y/o 46.5*
> 70 y/o 92
Hemoglobin < 13 g/dl 57.9†
> = 13 g/dl 89.4
Statistically significant differences in CD39 activity. Stage, age, and hemoglobin levels were associated with statistically significant differences in the 
enzymatic activity of CD39 in patients with CLL. A history of chemotherapy was associated with a marginally significant trend towards decreased 
CD39 activity in CLL. Leukocyte and platelet count, gender, and length of time since diagnosis were not associated with differences in CD39 
activity.
*p = 0.002
**p = 0.08
†p = 0.03Journal of Translational Medicine 2007, 5:23 http://www.translational-medicine.com/content/5/1/23
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(Table 3). FACS data in normal and malignant lym-
phocytes is summarized in Figures 2 and 3.
RT-PCR
We have recently identified two splice variants of CD39 in
addition to the full length form of the molecule. One of
these splice variants, called 1.5, has been shown to
decrease the activity of CD39 when co-expressed with full
length CD39 in COS cells [34]. The effects of the other
variant (1.3), are less clear, but it may enhance CD39
activity when co-expressed with full length CD39 with or
without variant 1.5[34]. Normal T-lymphocytes express
high levels of full length CD39 and variable amounts of
variants 1.3 and 1.5 on a per positive cell basis. B-lym-
phocytes express relatively high levels of 1.3 compared to
T-lymphocytes or malignant B-lymphocytes. Semi-quanti-
tative RT-PCR on CLL lymphocytes showed increased
expression of 1.5 and full length CD39 and decreased
expression of 1.3 as compared to normal B-lymphocytes.
This unusual ratio of 1.3 to 1.5 may explain the relatively
low levels of enzyme activity as compared to the higher
levels of antigen observed in some CLL lymphocytes.
Interestingly, the antibody used for FACS, BU61, identi-
fies full length CD39 and 1.5, but not 1.3, thus, CD39
density on CLL cells may be slightly overestimated by
FACS relative to normal lymphocytes. However, splice
variants occur only in complexes with full length CD39.
Therefore, whereas per cell density may be slightly overes-
timated by FACS, percentage positivity would be unaf-
fected.
Platelet reactivity in CLL
Platelets from patients with CLL showed normal or exag-
gerated aggregation in response to ADP. Addition of 0.5–
1 million CLL cells to PRP decreased the platelet aggrega-
tion responses to ADP in all patients tested, although the
decrease was minimal in one patient (Figures 4 and 5). A
preliminary dose-response study showed that addition of
less than 0.5 million cells resulted in only a minimal
decrease in platelet response to ADP. Limitations in the
amount of cells and PRP available in this initial study pre-
cluded testing of larger quantities of cells.
Average area under the aggregation curve (AUC) for
patients was > 300 for 10 and 5 μM ADP (figure 5). In con-
trast, average AUC in controls was 255 and 242 for 10 and
5 μM ADP (data not shown). However, two patients had
AUC of > 400 at 5 μM and three had no decrement of
response at 2 μM ADP, suggesting hypersensitivity in
these patients. Interestingly, the patient who showed the
lowest decrease in platelet response to ADP had high base-
line responsiveness to ADP.
We previously demonstrated that in combined suspen-
sions of endothelial cells and platelets, no agonist could
activate or induce recruitment of platelets due to the pres-
ence of CD39. COS cell controls, which are CD39 nega-
tive, had no effect on platelet reactivity, suggesting that
this is a specific property of CD39 [35].
Discussion
We found that the majority of lymphocytes from CLL
patients express active CD39 on their surface. All CLL
patients had some level of CD39 activity. Overall, CLL
cells had a much higher level of CD39 activity than nor-
mal lymphocytes, although their level of expression was
equal to or slightly lower than that of normal B-lym-
phocytes when all cases of CLL were considered together.
However, when CLL patients were divided into two sub-
groups, stages 0–2 and stages 3–4, it was found that the
earlier stage CLL patients had higher CD39 activity than
normal B-lymphocytes, whereas later stage CLL patients
had lower CD39 activity than normal B-lymphocytes.
Some patients with stage 3 and 4 disease had very low lev-
els of activity, comparable to levels seen in normal T-lym-
phocytes and much lower than would be observed in
normal B-lymphocytes. Thus, CD39 activity varies widely
in CLL, from supra-normal levels, particularly in patients
with early disease, to sub-normal levels in patients with
more advanced disease. Interestingly, a similar pattern has
Table 3: CD39 expression on sub-types of normal lymphocytes
Lymphocyte sub-type Average % CD39+ cells (range) Mean expression of CD39 per cell
Total normal lymphocytes 20* (14–23) 2463** (1800–3000)
T-lymphocytes (CD3+) 8.2* (1.2–15) 1717* (900–2700)
CD4+ 9.1* (1.8–16) 1942* (1300–2700)
CD8+ 7.9* (0.7–22) 949*,† (400–1500)
B-lymphocytes (CD19+) 95 (87–99) 3640 (2100–5000)
Malignant B-lymphocytes 93 (61–100) 3480 (600–9000)
CD39 expression on normal lymphocytes. Results from FACS analysis of blood from 10 normal volunteers. Percentage CD39 expression is 
expressed as double positive cells as a percentage of the subtype of cells.
*p < 0.00001 for 2 tailed T-test versus normal B-lymphocytes
**p < 0.001 for 2 tailed T-test versus normal B-lymphocytes
†p < 0.0001 for 2-tailed T-test versus CD4+ lymphocytesJournal of Translational Medicine 2007, 5:23 http://www.translational-medicine.com/content/5/1/23
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been reported in melanoma cell lines, in which CD39 is
elevated as compared to normal melanocytes in well dif-
ferentiated melanoma and decreased in more advanced
stages of the disease [26].
Lower levels of CD39 were associated with younger age,
progression of disease, and later stage of the disorder. A
trend toward lower CD39 was seen in patients who had
received chemotherapy. Decreased levels of ADPase activ-
ity were observed in 2 of the 3 patients whose disease pro-
gressed during the study. In addition, decreased levels of
ATPase were seen in all three. It is therefore possible that
the ATPase activity of CD39 may be important in CLL over
and above its anti-thrombotic effect.
A limitation of our methodologic approach is the pres-
ence of normal T- or B-lymphocytes in preparations from
CLL patients. Since B-lymphocytes typically comprise 15–
20% of normal lymphocytes and normal lymphocytes are
a minority of the total lymphocytes in CLL patients, con-
tamination with normal B-lymphocytes should have little
effect on the overall results. Contamination with T-lym-
phocytes may have a greater impact in cases in which the
total leukocyte count is relatively low. We attempted to
minimize this potential confounding factor by carrying
out B-lymphocyte isolation in patients with relatively
lower leukocyte counts. Since T-lymphocytes have lower
CD39 expression and activity than B-lymphocytes, the
presence of varying quantities of T-lymphocytes may have
led to a falsely low level of apparent CD39 activity in
patients with lower leukocyte counts. A more rigorous
elimination of normal lymphocytes might enhance the
differences between earlier and later stages of disease and,
particularly, between patients with leukocyte counts of
greater or less than 20 × 103  leukocytes/μl, but it is
unlikely that the results would change substantially.
FACS of CD39 in normal T-lymphocytes Figure 2
FACS of CD39 in normal T-lymphocytes. Illustrations demonstrate typical results of FACS for a lymphocyte gate. A. Total T-
lymphocytes. Lymphocytes in the right upper quadrant (quadrant 2) are positive for both CD39 and CD3. B. CD4+ lym-
phocytes. C. CD8 positive lymphocytes.
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Thus, CD39 may be a marker of less aggressive disease and
a drop in CD39 may be indicative of progression of the
disease. Further work is required to elucidate the mecha-
nism by which CD39 acts on CLL cells. One possible
mechanism is via decreased sensitivity to apoptosis in
cells with lower CD39 levels. A recent publication demon-
strated that dendritic cells in CD39 null mice were resist-
ant to apoptosis due to exposure to ATP[18]. Interestingly,
another study suggests that CD39 reduces apoptosis in
endothelial cells, possibly by lowering ATP-induced apop-
tosis [36]. Preliminary data from our laboratory suggests
that CD39 transfection can increase apoptosis in response
to DNA damaging chemotherapy in Jurkat cells (unpub-
lished data). We therefore hypothesize that CD39 has
effects on leukocytes which differ from those on endothe-
lial cells. Alternatively, the different splice variants may
have different effects on apoptosis. Further studies in this
area should clarify these questions.
Because of the much higher load of CLL cells as compared
to normal B-lymphocytes, patients with CLL have a much
higher total body load of CD39. This excess of CD39 may
provide protection against thrombotic events by blocking
Typical results of platelet activation and recruitment as studied in vitro by platelet aggregometry Figure 4
Typical results of platelet activation and recruitment as studied in vitro by platelet aggregometry. Figures represent aggregation 
curves following addition of 10, 5, 2, and 1 μM ADP to A. PRP B PRP+106 CLL cells. An equal number of CLL cells was added 
to platelet poor plasma (PPP) in the latter test. Area under the curve was 250 units for 10 μM ADP, 165 for 5 μM, 152 for 2 
μM, and 51 for 1 μM ADP in the control curve and 170, 119, 26, and 7 units respectively for samples in which CLL cells had 
been added, indicating a significant decrease in the degree of aggregation when these lymphocytes were added.
A B
Typical FACS of normal and malignant B-lymphocytes Figure 3
Typical FACS of normal and malignant B-lymphocytes. A. 
Normal B-lymphocytes B. Malignant B-lymphocytes. The 
majority (> 90%) of both normal and malignant B-lym-
phocytes are positive for CD39 and the mean expression per 
cell is similar. However, the number of B-lymphocytes as a 
percentage of the total lymphocyte gate is higher. Expression 
of CD39, as measured by FACS, was not clearly greater in 
earlier stage CLL as opposed to normal B-lymphocytes or 
later stage CLL, although activity was greater in earlier stage 
disease.
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platelet activation and recruitment. Thus, platelet func-
tion tests demonstrated that in vitro, even a relatively small
number of CLL cells inhibited the platelet aggregation
response to ADP. Additionally, the finding of baseline
platelet hypersensitivity to ADP in two of the patients
tested suggests that the patients' platelets were exposed to
ADP in vivo to a lesser extent than normal. Therefore, the
CD39 on their lymphocytes may be metabolizing ADP in
their vascular environment. These findings may explain
the relatively low incidence of thrombosis in patients with
CLL as compared to patients with other malignancies. We
plan to perform cross-over experiments in which the
effects of patients' cells on normal PRP and of normal
lymphocytes on patients' and normal PRP are examined
to further explore this issue.
The correlation of higher CD39 levels with increasing age
in CLL is unexpected, as CD39 levels in normal lym-
phocytes have not been observed to vary with age in this
or previous studies [22]. This result may be indicative of a
change in the biology of the disease in more senior
patients. Others have observed that older patients with
CLL are less likely to die of the disease as compared with
younger patients [37]. This correlates with our observa-
tion that patients with earlier or less aggressive disease
tend to have higher CD39 levels than patients with later,
more aggressive disease. RT-PCR for splice variants
showed that the CD39 on CLL cells has a different profile
from that of CD39 on normal T- or B-lymphocytes. This
profile suggests a relative down-regulation of ADPase
activity in CD39 in CLL. This finding further supports the
hypothesis that CD39 is involved in the pathogenesis of
CLL and may explain why the abundance of CD39 in CLL
patients does not produce a more dramatic reduction of
the platelet response in this patient population.
Conclusion
CD39 is expressed and active on malignant cells in CLL.
The level of CD39 activity correlates with the stage of dis-
ease. A decrease in CD39 activity, though not necessarily
CD39 expression, is correlated with worsening of disease.
These findings suggest that CD39 may be involved in the
pathogenesis of CLL and that lymphocytes in CLL may
actually function as antithrombotic agents due to their
CD39 content and activity.
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